Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
Lais® allergoid tablets contain allergens that are modified by carbamylation. Due to their modified chemical structure, they are suitable for sublingual immunotherapy (SLIT) (13, 16, 17, 24). Based on their small molecule size of 12 to 40 kDa, they can be easily absorbed via the oral mucosa (1). In this review, we studied the efficacy of SLIT with carbamylated monomeric allergoid tablets in the treatment of grass pollen- and dust mite-induced allergic rhinoconjunctivitis on the basis of symptom and medication score improvements. Following a selective internet and databank search, six trials-some placebo-controlled-regarding the treatment of grass pollen- (n = 266) and dust mite-induced (n = 241) allergic rhinoconjunctivitis were used to draw conclusions regarding the clinical efficacy of allergoid tablets. The primary endpoints in these trials were decreases in the need for allergy medications and/or reductions in the occurrence of rhinoconjunctivitis symptoms. Data was recorded from patient diaries regarding their symptoms and medications used and conclusions were then drawn about the effectiveness and tolerabieity of Lais® tablets. The average improvement in symptom score in three trials of grass pollen allergy treatment was 34% in comparison to the placebo group. The treatment of dust mite-induced rhinoconjunctivitis produced an average symptom score improvement of 22% compared to the placebo or control groups. The intake of symptomatic rescue medication during allergoid tablet therapy declined. Treatment of grass pollen allergies and dust mite-induced rhinoconjunctivitis showed an average medication score improvement of 49% and 24%, respectively. Few side effects were documented in the trials and predominantly local effects were observed. Severe systemic side effects did not occur. On the basis of the trial results summarized in this review, we suggest that SLIT using Lais® sublingual tablets is an effective and well-tolerated form of treatment.
Mösges
R
R
Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University of Cologne, Kerpener Straße 62, Cologne, Germany. Ralph.Moesges@unikoeln.de
Ritter
B
B
Kayoko
G
G
Allekotte
S
S
D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage*; D000080384:Allergoids; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D052179:Antigens, Plant / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008925:Mites / Q000276:immunology; D010936:Plant Extracts / Q000008:administration & dosage*; D011058:Pollen / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D016896:Treatment Outcome
D000485:Allergens; D000080384:Allergoids; D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D052179:Antigens, Plant; D010936:Plant Extracts